What Does Kezar Life Sciences ($KZR) Do? – Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters
A clinical-stage biotech company developing treatments for autoimmune hepatitis and lupus nephritis via immunoproteasome inhibition technology, currently exploring strategic growth options.
Subscribe🏢 What kind of company is Kezar Life Sciences?
Kezar Life Sciences (KZR) is a biotech company researching next-generation small-molecule compounds to treat refractory autoimmune diseases and solid tumors. Headquartered in South San Francisco, California, the company holds technology that selectively inhibits the immunoproteasome, an intracellular protein degradation system. Its lead pipeline candidate, Zetomipzomib, is designed to suppress excessive immune responses while minimizing systemic immunosuppression side effects, and is currently in clinical trials targeting autoimmune hepatitis (AIH) and lupus nephritis (LN).
How does it make money?| Business Segment | Revenue Mix | Description |
|---|---|---|
| Clinical-Stage Pipeline | 0% | There is currently no product revenue; income is expected upon future technology licensing and product approvals. |
All product candidates are currently in the clinical stage, generating no direct revenue. The company is restructuring its organization and concentrating resources on its core pipeline to improve R&D efficiency, and milestone payments from global partnerships are expected to become its primary source of revenue going forward.
📐 Market Cap and Company Size
The market cap stands at $53.9M, roughly About 0% of Samsung Electronics' market cap. The company employs 9 people people.
As a typical clinical-stage biotech with a market cap of $53.9M, it is targeting the enormous autoimmune disease market. A notable feature is its current pursuit of strategic alternatives (such as M&A) to maximize corporate value.
📈 Kezar Life Sciences Outlook and Price Action
1-Year Price Performance
Analyst Consensus
52-Week Price RangeKezar has demonstrated its technological capability by securing positive data from the Phase 2a trial of its lead drug Zetomipzomib in autoimmune hepatitis. It is currently in discussions with regulators regarding entry into a Phase 2b trial, and is also seeking additional clinical progress in lupus nephritis. The company secured operating funding through 2027 via significant cost reductions, and its current EPS stands at $-6.18 dollars. Successful clinical results for its pipeline or news of a strategic partnership will serve as the key catalysts for a stock-price rebound going forward.
⚔️ Core Competitive Strengths and Risks
While the company possesses distinctive immunoproteasome inhibition technology, it faces the clinical-success uncertainty and ongoing funding risks typical of early-stage biotech companies.
💪 Core Competitive Strengths
⚠️ Core Risks
🔄 Competitors and Related (Beneficiary) Stocks
Major competitors include GlaxoSmithKline (GSK), AstraZeneca (AZN), and Roche (ROG), all dominant players in the lupus treatment market, as well as Aurinia Pharmaceuticals (AUPH), which already markets a lupus nephritis treatment.
Competitors| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
 AUPH | Aurinia Pharmaceuticals Inc | $16.11 | -0.9% | $2.1B | 7.0 | 3.5 | 66.12% | - |
| GSK | GSK Plc ADR | $48.12 | -1.1% | $96.4B | 15.2 | 4.2 | 29.69% | 3.89% |
| AZN | Astrazeneca plc | $159.64 | +1.7% | $247.6B | 23.9 | 4.9 | 21.99% | 2.09% |
 ROG | Rogers Corp | $132.68 | +2.3% | $2.4B | 76.3 | 2.0 | 2.6% | - |
Related stocks (beneficiaries)| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
 IONS | Ionis Pharmaceuticals Inc | $55.65 | -0.7% | $9.2B | - | 21.0 | -105.42% | - |
| MRNA | Moderna Inc | $136.62 | +0.7% | $54.5B | - | 8.1 | -39% | - |
 BEAM | Beam Therapeutics Inc | $24.37 | -3.2% | $2.5B | - | 2.4 | -8.08% | - |
✅ Investor Checkpoints
Kezar Life Sciences aims to open a new chapter in autoimmune treatment. Investors should pay close attention to the following points.
| Checkpoint | What to Verify | Current Status |
|---|---|---|
| 🧪 Zetomipzomib Phase 2b Trial | Confirmation of the next clinical design for the autoimmune hepatitis treatment and the pace of patient enrollment | In Progress |
| 🤝 Strategic Deal Announcement | News of a completed M&A by a global pharmaceutical company or a major technology out-licensing agreement | Needs Monitoring |
| 💰 Cash Burn Management | Status of quarterly operating cost reductions and financial stability following the organizational restructuring | Stable |
Given the nature of the biotech sector, the stock price can swing dramatically around data readouts, and clinical delays could increase the financial burden.
Kezar Life Sciences is a company with a pipeline of high technical potential. If its ongoing strategic transformation bears fruit, the stock has ample room to be re-rated as a premier biotech franchise in the autoimmune space.
Check Kezar Life Sciences' real-time quotes, technical indicators, and peer comparisons at a glance on US Stock Today's real-time dashboard.
Subscribe Today's 5 AI picks, all free